Covid-19 roundup: AstraZeneca's candidate could elicit immune response in older patients; The EMA could approve a vaccine with less than 50% efficacy — report
With permission to resume its Covid-19 trial in the US, AstraZeneca is back in the race for emergency approval. And early results suggest the candidate …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.